Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Abbott Spinoff AbbVie Begins Trading to Determine Value

Abbott Laboratories’ spinoff began trading on a “when issued” basis, with investors valuing the new Abbott at $47.9 billion and the new drug company AbbVie Inc. at $55.3 billion.

The when-issued trading will set stock prices and values for the two companies when they officially split on Jan 1. Abbott when-issued shares, which are trading under the ticker ABT-W, began trading at $29.05 and rose 4.3 percent to $30.30 at 4 p.m. New York time. AbbVie when-issued shares, trading under the ticker ABBV-W, opened at $37 and fell 5.4 percent to $35.

The secondary market for the when-issued shares is in parallel with regular Abbott stock, which fell less than 1 percent to $65.33. The Dec. 31 closing values of the when-issued shares will set the opening prices for the split companies when the break-up is complete and the two different stocks begin trading on Jan. 2.

Abbott is dividing the Abbott Park, Illinois-based company because the drug unit and other operations have grown into two distinct business lines, Chief Executive Officer Miles White has said. The split will enable investors to better value the two businesses, he said when the decision was announced last year. Stock for AbbVie, the drugmaker, will trade under the ticker ABBV while Abbott will keep its current ticker, ABT.

The company has sought to expand use of the anti-inflammatory injection Humira, the world’s best-selling medicine with $7.93 billion in revenue last year, with new indications beyond rheumatoid arthritis, such as ulcerative colitis and pediatric Crohn’s disease. Abbott also is testing drugs to treat hepatitis C and has a rheumatoid arthritis pill in development with Belgian drugmaker Galapagos NV.

Abbott is the world’s biggest manufacturer of drug-coated stents, including its top product Xience. The new Abbott will also run the current company’s medical-device, diagnostic equipment, baby food and generic drug businesses.

In October, the company announced that AbbVie will pay an annual dividend of $1.60 a share, while Abbott shareholders will get 56 cents a year. Abbott will have a tax rate of 21.5 percent, while AbbVie’s rate will be 22 percent.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.